Henry Schein (HSIC) : North Point Portfolio Managers Corpoh scooped up 718 additional shares in Henry Schein during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 25, 2016. The investment management firm now holds a total of 114,990 shares of Henry Schein which is valued at $19,398,813.Henry Schein makes up approximately 3.73% of North Point Portfolio Managers Corpoh’s portfolio.
Henry Schein opened for trading at $168.86 and hit $171.21 on the upside on Monday, eventually ending the session at $171, with a gain of 1.36% or 2.3 points. The heightened volatility saw the trading volume jump to 5,84,507 shares. Company has a market cap of $14,012 M.
Other Hedge Funds, Including , Davenport Co boosted its stake in HSIC in the latest quarter, The investment management firm added 1,867 additional shares and now holds a total of 119,222 shares of Henry Schein which is valued at $20,112,751. Henry Schein makes up approx 0.31% of Davenport Co’s portfolio. Legacy Private Trust added HSIC to its portfolio by purchasing 4,620 company shares during the most recent quarter which is valued at $789,235. Henry Schein makes up approx 0.12% of Legacy Private Trust’s portfolio.Delta Capital Management reduced its stake in HSIC by selling 140 shares or 6.13% in the most recent quarter. The Hedge Fund company now holds 2,145 shares of HSIC which is valued at $366,430. Henry Schein makes up approx 0.25% of Delta Capital Management’s portfolio.Fisher Asset Management reduced its stake in HSIC by selling 2,490 shares or 0.5% in the most recent quarter. The Hedge Fund company now holds 499,512 shares of HSIC which is valued at $85,331,635. Henry Schein makes up approx 0.17% of Fisher Asset Management’s portfolio.Jaffetilchin Investment Partners reduced its stake in HSIC by selling 1,384 shares or 40.54% in the most recent quarter. The Hedge Fund company now holds 2,030 shares of HSIC which is valued at $345,059. Henry Schein makes up approx 0.11% of Jaffetilchin Investment Partners’s portfolio.
On the company’s financial health, Henry Schein reported $1.67 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Feb 10, 2016. Analyst had a consensus of $1.65. The company had revenue of $2850.91 million for the quarter, compared to analysts expectations of $2817.65 million. The company’s revenue was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.56 EPS.
Many Wall Street Analysts have commented on Henry Schein. Henry Schein was Initiated by Credit Suisse to “Neutral” on Mar 16, 2016. Barrington Research Upgraded Henry Schein on Mar 1, 2016 to ” Outperform”, Price Target of the shares are set at $182.Company shares were Reiterated by Piper Jaffray on Feb 11, 2016 to “Neutral”, Firm has raised the Price Target to $ 159 from a previous price target of $158 .
Henry Schein Inc. provides health care products and services to office-based dental animal health and medical practitioners. The Company operates its business through two segments: health care distribution and technology and value-added services. The health care distribution segment distributes consumable products laboratory products equipment repair services branded and generic pharmaceuticals vaccines surgical products diagnostic tests infection-control products and vitamins among others. The Company’s global technology and value-added services segment provides software technology and other value-added services to health care practitioners. Its offerings include practice management software systems for dental and medical practitioners and animal health clinics. Its value-added practice solutions include financial services on a non-recourse basis e-services practice technology network and hardware services as well as continuing education services for practitioners.